Jiangxi Synergy Pharmaceutical Faces Evaluation Shift Amidst Declining Profitability Trends

Jiangxi Synergy Pharmaceutical Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the company's technical score, which has been influenced by various underlying trends. The company has maintained a net-debt-free status, which is a positive aspect of its financial health. However, it has faced challenges in long-term growth, with net sales increasing at an annual rate of 11.69% while operating profit has shown a decline of 3.98% over the past five years. The return on equity stands at an average of 6.92%, indicating modest profitability relative to shareholders' funds. In terms of performance, Jiangxi Synergy has reported negative results for the last eight consecutive quarters, with the lowest operating profit recorded at CNY 21.86 million and an operating profit margin of 10.54%. Over the past year, the stock has generated a return of 13.74%, which is notably lower than the market's performance, specifically the China Shanghai Composite's return of 24.01%. This evaluation adjustment highlights the company's current market position and performance indicators without delving into specific financial trend grades. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.